probenecid has been researched along with Parkinson Disease in 60 studies
Probenecid: The prototypical uricosuric agent. It inhibits the renal excretion of organic anions and reduces tubular reabsorption of urate. Probenecid has also been used to treat patients with renal impairment, and, because it reduces the renal tubular excretion of other drugs, has been used as an adjunct to antibacterial therapy.
probenecid : A sulfonamide in which the nitrogen of 4-sulfamoylbenzoic acid is substituted with two propyl groups.
Parkinson Disease: A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Probenecid was administered to 7 unipolar depressed patients, 7 parkinsonians and 7 extrapyramidal patients with senile dementia matched for age and sex." | 3.66 | Biogenic amine disturbances in cerebrospinal fluid in parkinsonism and unipolar depression: use of the probenecid method. ( Mendlewicz, J; Noel, G; Vanderheyden, JE, 1981) |
| "The probenecid technique was used in study of the central dopamine DA metabolism in patients with depressions, psychotic disorders, and Parkinson's disease." | 3.65 | Dopamine metabolism in depressions, psychoses, and Parkinson's disease: the problem of the specificity of biological variables in behaviour disorders. ( Korf, J; Praag, HM; Schut, T, 1975) |
| "Paeonol treatment decreased MPTP/p‑induced oxidative stress, as determined by evaluating the activity levels of superoxide dismutase, catalase and glutathione." | 1.43 | Therapeutic effects of paeonol on methyl-4-phenyl-1,2,3,6-tetrahydropyridine/probenecid-induced Parkinson's disease in mice. ( Chen, YH; Liu, H; Qu, HD; Shi, X, 2016) |
| "Animal models of Parkinson's disease have been widely used for investigating the mechanisms of neurodegenerative process and for discovering alternative strategies for treating the disease." | 1.35 | Restorative effect of endurance exercise on behavioral deficits in the chronic mouse model of Parkinson's disease with severe neurodegeneration. ( Kurz, MJ; Lau, YS; Pothakos, K, 2009) |
| "Probenecid was administered to 7 unipolar depressed patients, 7 parkinsonians and 7 extrapyramidal patients with senile dementia matched for age and sex." | 1.26 | Serotonin and dopamine disturbances in patients with unipolar depression and Parkinsonism. ( Mendlewicz, J; Noel, G; Vanderheyden, JE, 1981) |
| "Six patients with Parkinson's disease and five controls were premedicated with probenecid and the peripheral decarboxylase inhibitor alpha-methyldopathydrazine (Carbidopa) before intravenous administration of 50 muc of 14C-L-dopa in tracer quantity." | 1.26 | 14C-homovanillic acid in the cerebrospinal fluid of parkinsonian patients after intravenous 14C-L-dopa. ( Bowers, MB; Extein, I; Roth, RH; Van Woert, M, 1976) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 46 (76.67) | 18.7374 |
| 1990's | 1 (1.67) | 18.2507 |
| 2000's | 4 (6.67) | 29.6817 |
| 2010's | 7 (11.67) | 24.3611 |
| 2020's | 2 (3.33) | 2.80 |
| Authors | Studies |
|---|---|
| Zhang, M | 1 |
| Zhang, Y | 2 |
| Niu, M | 1 |
| Zhu, Y | 1 |
| Tong, S | 1 |
| Kou, X | 1 |
| Yang, W | 1 |
| Hao, W | 1 |
| Meng, Z | 1 |
| Ding, S | 1 |
| Li, X | 1 |
| Zhang, T | 1 |
| Huang, W | 1 |
| Xu, L | 1 |
| Yang, J | 1 |
| Gu, X | 1 |
| Alvarez-Fischer, D | 1 |
| Noelker, C | 1 |
| Grünewald, A | 1 |
| Vulinović, F | 1 |
| Guerreiro, S | 1 |
| Fuchs, J | 1 |
| Lu, L | 1 |
| Lombès, A | 1 |
| Hirsch, EC | 1 |
| Oertel, WH | 1 |
| Michel, PP | 1 |
| Hartmann, A | 1 |
| Rekha, KR | 1 |
| Selvakumar, GP | 1 |
| Heng, Y | 1 |
| Zhang, QS | 1 |
| Mu, Z | 1 |
| Hu, JF | 1 |
| Yuan, YH | 1 |
| Chen, NH | 1 |
| Shi, X | 1 |
| Chen, YH | 1 |
| Liu, H | 1 |
| Qu, HD | 1 |
| Gu, PS | 1 |
| Moon, M | 1 |
| Choi, JG | 1 |
| Oh, MS | 1 |
| Pothakos, K | 2 |
| Kurz, MJ | 2 |
| Lau, YS | 5 |
| Barber-Singh, J | 1 |
| Seo, BB | 1 |
| Nakamaru-Ogiso, E | 1 |
| Matsuno-Yagi, A | 1 |
| Yagi, T | 1 |
| Patki, G | 1 |
| Das-Panja, K | 1 |
| Le, WD | 1 |
| Ahmad, SO | 1 |
| Carta, AR | 1 |
| Carboni, E | 1 |
| Spiga, S | 1 |
| Meredith, GE | 1 |
| Totterdell, S | 1 |
| Petroske, E | 1 |
| Santa Cruz, K | 1 |
| Callison, RC | 1 |
| Al-Jarrah, M | 1 |
| Novikova, L | 1 |
| Smirnova, IV | 1 |
| Stehno-Bittel, L | 1 |
| Korczyn, AD | 1 |
| Vanderheyden, JE | 2 |
| Noel, G | 2 |
| Mendlewicz, J | 2 |
| Growdon, JH | 2 |
| Melamed, E | 1 |
| Logue, M | 2 |
| Hefti, F | 1 |
| Wurtman, RJ | 1 |
| Cramer, H | 3 |
| Warter, JM | 1 |
| Renaud, B | 1 |
| de Jong, PJ | 1 |
| Lakke, JP | 5 |
| Teelken, AW | 1 |
| Cunha, L | 1 |
| Gonçalves, AF | 1 |
| Oliveira, C | 1 |
| Dinis, M | 1 |
| Amaral, R | 1 |
| Kartzinel, R | 1 |
| Ebert, MH | 1 |
| Chase, TN | 12 |
| Rinne, UK | 5 |
| Marttila, R | 2 |
| Sonninen, V | 5 |
| Extein, I | 1 |
| Van Woert, M | 1 |
| Roth, RH | 1 |
| Bowers, MB | 3 |
| Praag, HM | 1 |
| Korf, J | 6 |
| Schut, T | 3 |
| Kawachi, M | 1 |
| Kono, N | 1 |
| Kiyokawa, H | 1 |
| Mineo, I | 1 |
| Nakajima, H | 1 |
| Shimizu, T | 1 |
| Yorifuji, S | 1 |
| Kuwajima, M | 1 |
| Tarui, S | 1 |
| Gibson, CJ | 1 |
| Caranasos, GJ | 1 |
| Stewart, RB | 1 |
| Cluff, LE | 1 |
| Van Woert, MH | 3 |
| Weintraub, MI | 1 |
| van Praag, HM | 5 |
| Minderhoud, JM | 1 |
| Ng, LK | 5 |
| Gordon, EK | 3 |
| Oliver, J | 1 |
| Véron, JP | 1 |
| Mérienne, L | 1 |
| Garelis, E | 1 |
| Young, SN | 1 |
| Lal, S | 1 |
| Sourkes, TL | 1 |
| Riekkinen, P | 1 |
| Laaksonen, H | 1 |
| Schut, D | 1 |
| Nienhuis, RJ | 1 |
| Barbeau, A | 1 |
| Siirtola, T | 1 |
| Molnár, G | 1 |
| Fodor, A | 1 |
| Karczag, I | 1 |
| Szilágyi, A | 1 |
| Ujvárosi, I | 1 |
| Woods, AC | 1 |
| Glaubiger, GA | 1 |
| Gottfries, CG | 1 |
| Kjällquist, A | 1 |
| Pontén, U | 1 |
| Roos, BE | 4 |
| Sundbärg, G | 1 |
| Chase, RN | 1 |
| Schnur, JA | 1 |
| Brody, JA | 1 |
| Johansson, B | 1 |
| Olsson, R | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Effects of Supplementing Tyrosine on Blood Pressure in Parkinson's Disease[NCT01676103] | Phase 1/Phase 2 | 40 participants (Actual) | Interventional | 2012-09-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
4 reviews available for probenecid and Parkinson Disease
| Article | Year |
|---|---|
Clinically desirable drug interactions.
Topics: Aminoglycosides; Amoxicillin; Ampicillin; Antacids; Anti-Bacterial Agents; Anti-Infective Agents; Ba | 1985 |
Monoamine metabolites in lumbar CSF: the question of their origin in relation to clinical studies.
Topics: Animals; Biological Transport, Active; Brain; Cats; Cerebral Ventricles; Cerebrospinal Fluid; Choroi | 1974 |
Serotonergic mechanisms and extrapyramidal function in man.
Topics: 5-Hydroxytryptophan; Carbidopa; Cerebellar Diseases; Creutzfeldt-Jakob Syndrome; Down Syndrome; Extr | 1974 |
[Biochemical and clinical correlations in Parkinson's disease].
Topics: Brain; Dihydroxyphenylalanine; Dopamine; Homovanillic Acid; Humans; Movement Disorders; Norepinephri | 1972 |
2 trials available for probenecid and Parkinson Disease
| Article | Year |
|---|---|
[Predictive value of the probenecid test for the effect of L-DOPA therapy in Parkinson's disease].
Topics: Adult; Aged; Clinical Trials as Topic; Dihydroxyphenylalanine; Dopamine; Evaluation Studies as Topic | 1972 |
Parkinson disease treated with a suspected dopamine receptor agonist.
Topics: Adult; Aged; Amantadine; Aromatic Amino Acid Decarboxylase Inhibitors; Benztropine; Dihydroxyphenyla | 1974 |
54 other studies available for probenecid and Parkinson Disease
| Article | Year |
|---|---|
[Dihydromyricetin alleviates pyroptosis and necroptosis in mice with MPTP-induced chronic Parkinson's disease by inducing autophagy].
Topics: Animals; Autophagy; Interleukin-6; Mice; Mice, Inbred C57BL; Necroptosis; Neuroinflammatory Diseases | 2023 |
Molecular Regulatory Mechanism and Toxicology of Neurodegenerative Processes in MPTP/Probenecid-Induced Progressive Parkinson's Disease Mice Model Revealed by Transcriptome.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Disease Models, Animal; Gen | 2021 |
Probenecid potentiates MPTP/MPP+ toxicity by interference with cellular energy metabolism.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; Animals; Corpus Striatum; | 2013 |
Gene expression regulation of Bcl2, Bax and cytochrome-C by geraniol on chronic MPTP/probenecid induced C57BL/6 mice model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Acyclic Monoterpenes; Animals; Apoptosis; bcl-2-Associ | 2014 |
Ginsenoside Rg1 attenuates motor impairment and neuroinflammation in the MPTP-probenecid-induced parkinsonism mouse model by targeting α-synuclein abnormalities in the substantia nigra.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; alpha-Synuclein; Animals; Anti-Inflammatory Agents; Di | 2016 |
Therapeutic effects of paeonol on methyl-4-phenyl-1,2,3,6-tetrahydropyridine/probenecid-induced Parkinson's disease in mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Acetophenones; Animals; Behavior, Animal; Brain-Derive | 2016 |
Mulberry fruit ameliorates Parkinson's-disease-related pathology by reducing α-synuclein and ubiquitin levels in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/probenecid model.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; alpha-Synuclein; Animals; Antioxidants; Corpus Striatu | 2017 |
Restorative effect of endurance exercise on behavioral deficits in the chronic mouse model of Parkinson's disease with severe neurodegeneration.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amphetamine; Animals; Ataxia; Disease Models, Animal; | 2009 |
Neuroprotective effect of long-term NDI1 gene expression in a chronic mouse model of Parkinson disorder.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Chronic Disease; Disease Mo | 2009 |
Neuroprotective effects and mechanisms of exercise in a chronic mouse model of Parkinson's disease with moderate neurodegeneration.
Topics: Adjuvants, Pharmaceutic; Animals; Biomarkers; Brain-Derived Neurotrophic Factor; Corpus Striatum; Di | 2011 |
The MPTP/probenecid model of progressive Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Chromatography, High Pressu | 2013 |
Lysosomal malfunction accompanies alpha-synuclein aggregation in a progressive mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; alpha-Synuclein; Animals; Cell Death; Cerebral Cortex; | 2002 |
Endurance exercise promotes cardiorespiratory rehabilitation without neurorestoration in the chronic mouse model of parkinsonism with severe neurodegeneration.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Calorimetry, Indirect; Citr | 2007 |
The probenecid test.
Topics: Blood-Brain Barrier; Brain; Dopamine; Humans; Neurotransmitter Agents; Norepinephrine; Parkinson Dis | 1983 |
Biogenic amine disturbances in cerebrospinal fluid in parkinsonism and unipolar depression: use of the probenecid method.
Topics: Aged; Dementia; Depressive Disorder; Dopamine; Female; Homovanillic Acid; Humans; Hydroxyindoleaceti | 1981 |
Serotonin and dopamine disturbances in patients with unipolar depression and Parkinsonism.
Topics: Brain; Depressive Disorder; Dopamine; Female; Homovanillic Acid; Humans; Hydroxyindoleacetic Acid; M | 1981 |
Effects of oral L-tyrosine administration on CSF tyrosine and homovanillic acid levels in patients with Parkinson's disease.
Topics: Administration, Oral; Chromatography, High Pressure Liquid; Homovanillic Acid; Humans; Hydroxyindole | 1982 |
Analysis of neurotransmitter metabolites and adenosine 3',5'-monophosphate in the CSF of patients with extrapyramidal motor disorders.
Topics: Adult; Basal Ganglia Diseases; Cyclic AMP; Female; Homovanillic Acid; Humans; Huntington Disease; Hy | 1984 |
CSF GABA levels in Parkinson's disease.
Topics: Dopamine; gamma-Aminobutyric Acid; Humans; Levodopa; Parkinson Disease; Probenecid | 1984 |
Homovanillic acid in the cerebrospinal fluid of Parkinsonian patients.
Topics: Female; Homovanillic Acid; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Phenylacetates; P | 1983 |
Intravenous probenecid loading. Effects on plasma and cerebrospinal fluid probenecid levels and on monoamine metabolites in cerebrospinal fluid.
Topics: Administration, Oral; Adult; Dose-Response Relationship, Drug; Female; Homovanillic Acid; Humans; Hu | 1976 |
Brain dopamine turnover and the relief of parkinsonism.
Topics: Brain; Bromocriptine; Dopamine; Homovanillic Acid; Humans; Hydroxyindoleacetic Acid; Parkinson Disea | 1977 |
Brain dopamine turnover and the relief of parkinsonism.
Topics: Aromatic Amino Acid Decarboxylase Inhibitors; Bromocriptine; Homovanillic Acid; Humans; Hydroxyindol | 1977 |
14C-homovanillic acid in the cerebrospinal fluid of parkinsonian patients after intravenous 14C-L-dopa.
Topics: Aged; Brain; Carbidopa; Carboxy-Lyases; Dopamine; Female; Homovanillic Acid; Humans; Levodopa; Male; | 1976 |
Dopamine metabolism in depressions, psychoses, and Parkinson's disease: the problem of the specificity of biological variables in behaviour disorders.
Topics: Adjustment Disorders; Bipolar Disorder; Brain; Carboxy-Lyases; Depression; Dihydroxyphenylalanine; D | 1975 |
Decreased renal clearance of xanthine and hypoxanthine in a patient with renal hypouricemia: a new defect in renal handling of purines.
Topics: Humans; Hypoxanthine; Hypoxanthines; Kidney Diseases; Male; Metabolic Clearance Rate; Middle Aged; P | 1992 |
CSF monoamine metabolite levels in Alzheimer's and Parkinson's disease.
Topics: Adult; Aged; Alzheimer Disease; Female; Glycols; Homovanillic Acid; Humans; Hydroxyindoleacetic Acid | 1985 |
Predicting the response to levodopa.
Topics: Calcinosis; Capillaries; Central Nervous System; Cerebrospinal Fluid; Cerebrovascular Disorders; Dih | 1971 |
Predicting response to levodopa.
Topics: Brain; Dihydroxyphenylalanine; Dopamine; Humans; Parkinson Disease; Phenylacetates; Probenecid; Time | 1971 |
The probenecid test in Parkinson's disease.
Topics: Humans; Parkinson Disease; Phenylacetates; Probenecid | 1972 |
Clinical significance of probenecid test.
Topics: Brain Diseases; Homovanillic Acid; Humans; Hydroxyindoleacetic Acid; Parkinson Disease; Phenylacetat | 1973 |
Probenecid test in Parkinson's disease.
Topics: Homovanillic Acid; Humans; Methods; Parkinson Disease; Probenecid | 1971 |
3 -Methoxy- 4 -hydroxyphenylethylene glycol in human cerebrospinal fluid.
Topics: Chromatography, Gas; Depression; Dihydroxyphenylalanine; Down Syndrome; Ethers; Glycols; Humans; Hyd | 1971 |
[The probenecid test. Evaluation in clinical medicine of cerebral metabolism of serotonin and dopamine].
Topics: Biological Transport, Active; Brain; Depression; Dopamine; Down Syndrome; Humans; Indoleacetic Acids | 1972 |
Norepinephrine metabolism in the central nervous system of man: studies using 3-methoxy-4-hydroxyphenylethylene glycol levels in cerebrospinal fluid.
Topics: Adolescent; Adult; Aged; Antihypertensive Agents; Carbon Radioisotopes; Cerebrospinal Fluid; Child; | 1973 |
Central monoamine metabolism in man. Effect of putative dopamine receptor agonists and antagonists.
Topics: Adult; Basal Ganglia Diseases; Brain; Central Nervous System Diseases; Dopamine; Haloperidol; Homova | 1973 |
Effect of probenecid on levels of cyclic AMP in human cerebrospinal fluid.
Topics: Adult; Aged; Cerebellar Diseases; Cyclic AMP; Female; Humans; Male; Middle Aged; Muscular Diseases; | 1972 |
Adenosine 3',5'-monophosphate in cerebrospinal fluid. Effect of drugs and neurologic disease.
Topics: Adolescent; Adult; Aged; Cerebellar Diseases; Child; Cyclic AMP; Dihydroxyphenylalanine; Female; Hom | 1973 |
Serotonergic-dopaminergic interactions and extrapyramidal function.
Topics: Biogenic Amines; Brain; Dihydroxyphenylalanine; Dopamine; Extrapyramidal Tracts; Humans; Huntington | 1974 |
Dopaminergic nervous transmission in Parkinson's disease.
Topics: Acetylcholinesterase; Aromatic Amino Acid Decarboxylase Inhibitors; Autopsy; Brain; Brain Chemistry; | 1974 |
Clinical studies of dopaminergic mechanisms.
Topics: Antiparkinson Agents; Dioxoles; Dopamine; Drug Evaluation; Haloperidol; Homovanillic Acid; Humans; L | 1974 |
Parkinson's disease and amine metabolites in cerebrospinal fluid: implications for L-Dopa therapy.
Topics: Aged; Aromatic Amino Acid Decarboxylase Inhibitors; Depression, Chemical; Dopa Decarboxylase; Drug C | 1974 |
Acid monoamine metabolites in the cerebrospinal fluid of patients with Parkinson's disease.
Topics: Female; Humans; Hydroxyindoleacetic Acid; Male; Middle Aged; Parkinson Disease; Phenylacetates; Prob | 1972 |
Acid monoamine metabolites in the cerebrospinal fluid of Parkinsonian patients treated with levodopa alone or combined with a decarboxylase inhibitor.
Topics: Adult; Aged; Carboxy-Lyases; Dihydroxyphenylalanine; Dopamine; Dose-Response Relationship, Drug; Dru | 1973 |
5-Hydroxyindoleacetic acid in cerebrospinal fluid.
Topics: Adult; Age Factors; Brain Diseases; Brain Stem; Depression; Epilepsy; Humans; Hydroxyindoleacetic Ac | 1973 |
Cerebrospinal fluid pH and monoamine and glucolytic metabolites in Alzheimer's disease.
Topics: Affective Symptoms; Aged; Bicarbonates; Carbon Dioxide; Dementia; Female; Glycolysis; Homovanillic A | 1974 |
Fusaric acid in Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Dihydroxyphenylalanine; Female; Homovanillic Acid; Humans; Hydroxyindole | 1974 |
Central monoamine metabolism in Parkinson's disease.
Topics: Adult; Aged; Dihydroxyphenylalanine; Dopamine; Evaluation Studies as Topic; Female; Humans; Hydroxyi | 1972 |
Parkinsonism-dementia and amyotrophic lateral sclerosis of Guam. Effect of probenecid on monoamine catabolite levels in cerebrospinal fluid.
Topics: Adult; Aged; Amyotrophic Lateral Sclerosis; Dihydroxyphenylalanine; Dopamine; Female; Humans; Hydrox | 1971 |
5-Hydroxyindoleacetic acid in cerebrospinal fluid of patients with Parkinson's syndrome treated with L dopa.
Topics: Adult; Aged; Dihydroxyphenylalanine; Female; Humans; Hydroxyindoleacetic Acid; Male; Middle Aged; Pa | 1971 |
[Clinical pharmacology (11): diagnostic methods].
Topics: Bipolar Disorder; Diagnostic Uses of Chemicals; Humans; Hydroxyindoleacetic Acid; Parkinson Disease; | 1970 |
Homovanillic acid (HVA) and 5-hydroxyindoleacetic acid (5HIAA) during L-dopa therapy of Parkinson's disease.
Topics: Dementia; Dihydroxyphenylalanine; Humans; Hydroxyindoleacetic Acid; Parkinson Disease; Phenylacetate | 1970 |
Retarded depression and the dopamine metabolism.
Topics: Brain; Depression; Dopamine; Humans; Motor Activity; Parkinson Disease; Phenylacetates; Probenecid; | 1971 |
Concentrations of 5-hydroxyindoleacetic acid and homovanillic acid in the cerebrospinal fluid after treatment with probenecid in patients with Parkinson's disease.
Topics: Aged; Chemistry, Clinical; Female; Humans; Hydroxyindoleacetic Acid; Intracranial Arteriosclerosis; | 1968 |